Sort
4,870 grants matching “glp 1”
Development of a monoclonal antibody to reverse overdose from fentanyl and its analogs: from manufacturing to clinical trials
$3,410,308Marco Pravetoni · University Of Washington · UH3 · FY2025 · DA
Sustained Long Acting Prevention Against HIV Program Operation
$3,346,920Thomas Hope · Northwestern University At Chicago · UM1 · FY2019 · AI
AAV-mediated editing to treat human autosomal dominant hearing loss DFNA41 and DFNA2
$3,314,560Zheng-Yi Chen · Massachusetts Eye And Ear Infirmary · U01 · FY2024 · TR
Development of an VEE Replicon Vaccine Against Smallpox
$3,300,000Alphavax Human Vaccines, Inc. · UC1 · FY2005 · AI
A fully-implanted spinal cord stimulation system to restore sensation and relieve phantom limb pain after lower-limb amputation
$3,242,520Lee E Fisher · University Of Pittsburgh At Pittsburgh · UG3 · FY2025 · NS
AAV-mediated editing to treat human autosomal dominant hearing loss DFNA41 and DFNA2
$3,227,062Zheng-Yi Chen · Massachusetts Eye And Ear Infirmary · U01 · FY2025 · TR
UTHSC Regional Biocontainment Laboratory: Upgrade of Facility and Building System
$3,211,742Colleen B Jonsson · University Of Tennessee Health Sci Ctr · G20 · FY2021 · AI
Continuation of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) Study
$3,162,825Heidi Krause-Steinrauf · George Washington University · U01 · FY2022 · DK
A Single Ascending Dose / Multiple Ascending Dose Phase I study of the GSM 776890 in healthy normal subjects
$3,156,733Steven Lee Wagner · University Of California, San Diego · R01 · FY2021 · AG
Enhancing Chimeric Antigen Receptor T Cell Therapies for HematologicMalignancies: Beyond CART 19
$3,119,164Carl H. June · University Of Pennsylvania · P01 · FY2024 · CA
WNPRC ANIMAL SERVICES DIVISION
$3,098,062Saverio Vincent Capuano · University Of Wisconsin-Madison · P51 · FY2010 · RR
Novel, Non-Opioid, Non-Addictive Intrathecal Therapy for the Treatment of Chronic Pain
$3,072,761James N Campbell · Centrexion Therapeutics Corporation · UH3 · FY2023 · NS
Engineered metabolite-based nanoparticles for immunomodulation of macrophages to treat obesity
$3,065,252Alireza Hassani Najafabadi · Terasaki Institute For Biomedical Innovation · R01 · FY2025 · DK
A Therapeutic Agent to Lower the Level of Synthetic Opioids in the Body
$3,051,790Xinhua Li · Clear Scientific, Llc · UG3 · FY2024 · DA
A Therapeutic Agent to Lower the Level of Synthetic Opioids in the Body
$3,035,865Xinhua Li · Clear Scientific, Llc · UG3 · FY2023 · DA
Targeted Bone Regeneration via Activation of Resident Stem Cells
$3,025,490Sharie Haugabook · National Center For Advancing Translational Sciences · ZIA · FY2022 · TR
DEVELOPMENT OF AN ORAL DRUG FOR SMALLPOX TREATMENT
$3,005,821Chimerix, Inc. · U01 · FY2003 · AI
Clinical Psychoneuroendocrinology and Neuropsychopharmacology (CPN)
$3,001,225Lorenzo Leggio · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2015 · AA
Development of a Next Generation Vaccine for Smoking Cessation and Relapse Preven
$2,996,608Lloyd Patrick Johnston · Selecta Biosciences, Inc. · RC3 · FY2010 · DA
Clinical Psychoneuroendocrinology and Neuropsychopharmacology (CPN)
$2,972,035Lorenzo Leggio · National Institute On Drug Abuse · ZIA · FY2023 · DA
ACE2 immunodecoys for long-lasting immunoprophylaxis against sarbecovirus and merbecoviruses that target human ACE2
$2,937,578Samuel Lai · Univ Of North Carolina Chapel Hill · R01 · FY2025 · AI
Development of a bioabsorbable, subcutaneous, extended-release buprenorphine implant for opioid use disorder
$2,932,500Steven M Cohen · Drug Delivery Company, Llc, The · UG3 · FY2025 · DA
Targeting viral envelopes with antiviral peptides and peptoids and degraders, and surface proteins with small molecules
$2,909,919Nam-Joon Cho · Stanford University · U19 · FY2022 · AI
Regulators of Food Intake
$2,908,174Jonathan Krakoff · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2025 · DK
Enhancing Chimeric Antigen Receptor T Cell Therapies for Hematologic Malignancies: Beyond CART 19
$2,897,444Carl H. June · University Of Pennsylvania · P01 · FY2017 · CA